Cargando…

Histone Deacetylase Inhibitors as Anticancer Drugs

Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransfer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eckschlager, Tomas, Plch, Johana, Stiborova, Marie, Hrabeta, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535906/ https://www.ncbi.nlm.nih.gov/pubmed/28671573 http://dx.doi.org/10.3390/ijms18071414

Ejemplares similares

The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells
por: Cerna, Tereza, et al.
Publicado: (2018)

The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells
por: Poljaková, Jitka, et al.
Publicado: (2008)

Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells
por: Hřebačková, Jana, et al.
Publicado: (2009)

DNA and histone deacetylases as targets for neuroblastoma treatment
por: Stiborová, Marie, et al.
Publicado: (2010)

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
por: Verza, Flávia Alves, et al.
Publicado: (2020)

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Antitheilerial Activity of the Anticancer Histone Deacetylase Inhibitors
por: Barman, Madhumanti, et al.
Publicado: (2021)

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
por: Miller, Claudia P., et al.
Publicado: (2011)

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
por: Mottamal, Madhusoodanan, et al.
Publicado: (2015)

Drug Sequestration in Lysosomes as One of the Mechanisms of Chemoresistance of Cancer Cells and the Possibilities of Its Inhibition
por: Hraběta, Jan, et al.
Publicado: (2020)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Apoferritin Modified Magnetic Particles as Doxorubicin Carriers for Anticancer Drug Delivery
por: Blazkova, Iva, et al.
Publicado: (2013)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity
por: Huang, Wei-Jan, et al.
Publicado: (2012)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model
por: Pająk, Beata, et al.
Publicado: (2021)

Histone deacetylases as targets for antitrypanosomal drugs
por: Zuma, Aline A, et al.
Publicado: (2018)

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
por: Singh, Amit Kumar, et al.
Publicado: (2018)

Interpreting clinical assays for histone deacetylase inhibitors
por: Martinet, Nadine, et al.
Publicado: (2011)

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
por: Bishton, Mark J., et al.
Publicado: (2010)

Dual Inhibitors Against Topoisomerases and Histone Deacetylases
por: Seo, Young Ho
Publicado: (2015)

Histone Deacetylase Inhibitors and Diabetic Kidney Disease
por: Hadden, Mitchell J., et al.
Publicado: (2018)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)

Histone Deacetylase Inhibitors from Marine Invertebrates
por: Luparello, Claudio, et al.
Publicado: (2020)

The Impact of Fluorination on the Design of Histone Deacetylase Inhibitors
por: Tien Anh, Duong, et al.
Publicado: (2023)

The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
por: Vaca, Hugo Rolando, et al.
Publicado: (2021)

Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors
por: Autin, Pierre, et al.
Publicado: (2019)

Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma
por: Liu, Linlin, et al.
Publicado: (2018)

Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 Inhibitors
por: Martínez, Regina, et al.
Publicado: (2020)

Regulation of Immune Responses by Histone Deacetylase Inhibitors
por: Licciardi, Paul V., et al.
Publicado: (2012)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
por: Stintzing, Sebastian, et al.
Publicado: (2011)

Zinc binding groups for histone deacetylase inhibitors
por: Zhang, Lei, et al.
Publicado: (2018)

Valproic acid overcomes hypoxia-induced resistance to apoptosis
por: CIPRO, ŠIMON, et al.
Publicado: (2011)

Histone deacetylase inhibitors: clinical implications for hematological malignancies
por: Tambaro, Francesco Paolo, et al.
Publicado: (2010)

Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells
por: Wawruszak, Anna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b9uihpfp6mq764lis99dvo155c